Document Type

Article

Publication Date

11-26-2024

Comments

This article, first published by Frontiers Media, is the author's final published version in Frontiers in Pharmacology, Volume 15, 2024, Article number 1479804.

The published version is available at https://doi.org/10.3389/fphar.2024.1479804.

Copyright © 2024 Wang, Wan, You, Zheng, Xu, He, Peng, Jorge Luis, Feng, Xu, Li, Chong, Hai, Jia, Fang and Zhang

Abstract

OBJECTIVE: This study aims to conduct a systematic review and network meta-analysis to evaluate the efficacy and safety of specific corticosteroids, including but not limited to hydrocortisone, methylprednisolone, prednisolone, and dexamethasone, in the treatment of severe community-acquired pneumonia (SCAP). Efficacy will be assessed using specific outcomes, such as 30-day mortality and the requirement for mechanical ventilation. Safety evaluations will include adverse events like gastrointestinal bleeding and healthcare-associated infections. The study seeks to address the gaps identified in the latest guidelines regarding the optimal use of different corticosteroid types and to provide recommendations for clinical practice.

DATA SOURCES: This study conducted a comprehensive search of Medline, Embase, and the Cochrane Central Register of Controlled Trials, covering the period from inception until 22 June 2023. Randomized clinical trials for corticosteroid use among adults with SCAP were collected.

STUDY SELECTION: Two researchers independently assessed study eligibility based on titles and abstracts, with any disagreements resolved through discussion or consultation with a third researcher.

DATA EXTRACTION: Two researchers independently collected and clarified study details, with a third researcher adjudicating in case of disputes.

DATA SYNTHESIS: The data from 13 randomized clinical trials involving 2,495 patients, were analyzed using a random-effects model. Eleven trials were assessed as low risk, while two were assessed as high risk. Trials were rated as having low bias risk. Results, presented as risk ratios (RR) with a 95% confidence interval (CI), indicated that hydrocortisone outperformed prednisolone (RR 0.35; 95% CI 0.10-0.94), methylprednisolone (RR 0.41; 95% CI 0.15-0.89), and placebo (RR 0.35; 95% CI 0.16-0.59) in reducing 30-day mortality. A rankogram plot suggested that hydrocortisone had the highest probability of being the most effective treatment for this outcome within the analyzed group.

CONCLUSION: In this network meta-analysis, while hydrocortisone showed greater efficacy than prednisolone, methylprednisolone, and placebo in reducing 30-day mortality in patients with SCAP, further Randomized Controlled Trials (RCTs) are required to confirm these findings before drawing definitive conclusions.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=438389, identifier CRD42023438389.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Additional Files
Supplementary Material.docx (1520 kB)

PubMed ID

39660004

Language

English

Download

Share

COinS